|
Scott and Xioping: Xioping, I think you've covered the basics, except to say that MRE is so confident in its pipeline that the investor protection (poison pill) action the company took a few months ago said--if I recall accurately--that the company can't be bought out for less than over $90/share. The company also estimated that the pipeline of drugs that it's confident in is worth over $3 billion. These, however, are predictive, not certain, developments. What is certain is that the uses of adenoscine are expanding, such that MRE has continued to come out with earning surprises--again, not a sure thing in the future, but certainly a sign of the efficacious uses of adenoscine. If MEDR640 is approved, the profitibility of MRE is skyrocket. Approval, of course, is always a long and tough process, but the clinical trials for the uses of Adenoscine for detecting cardiac damage and for ensuring faster healing are, thus far, impressive. MRE is active both in its sponsorship of more R&D and in its attention to buying the rights of other discovered uses of Adenoscine and its cognate formulations. I'm sure the company will send you scientific articles about Adenoscine studies, as well as its past press releases concerning its poison pill package, etc. Harold V. |
